Desonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It is available as cream, ointment and lotion for topical use. MedsAcross supplies Desonide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Desonide Ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician.
Source: US FDA prescribing information
Desonide Ointment, 0.05% should be applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may be necessary. Desonide Ointment, 0.05% should not be used with occlusive dressings.
Source: US FDA prescribing information
Desonide Ointment, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Source: US FDA prescribing information
General - Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment. Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. Patients receiving superpotent corticosteroids should not be treated for more than two weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA suppressions.
Source: US FDA prescribing information
In controlled clinical trials, the total incidence of adverse reactions associated with the use of Desonide Ointment, 0.05% was approximately 6%. These adverse reactions were erythema, induration, pruritus, irritation, oiliness, and peripheral edema. The following additional local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in approximate decreasing order of occurrence: dryness, folliculitis, acneiform eruptions, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria, burning and hypopigmentation.
Source: US FDA prescribing information
Store at 20-25°C (68-77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
5 presentations of Desonide, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Desonide 0.05% creamTopicalGeneric name | — | US FDA | Available on request |
| Desonide 0.05% ointmentTopicalGeneric name | — | US FDA | Available on request |
| Desonide 0.5 mg/mL lotionTopicalGeneric name | — | US FDA | Available on request |
| Desonide 0.05% gelTopicalGeneric name | — | US FDA | Available on request |
| Tridesilon Cream 0.05% creamTopical | Encore Dermatology | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 4 January 1972 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Desonide in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 5 presentations of Desonide and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Desonide, including Tridesilon Cream.
Yes. The US FDA first approved Desonide on 4 January 1972, according to Drugs@FDA.
No listed presentation of Desonide is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Desonide is classified under ATC code D07AB08 (Desonide).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.